Fetuin-A levels in association with calcific aortic valve disease: A meta-analysis

IF 1.4 Q3 PERIPHERAL VASCULAR DISEASE Atherosclerosis plus Pub Date : 2023-09-26 DOI:10.1016/j.athplu.2023.09.004
Muhammad Omar Larik
{"title":"Fetuin-A levels in association with calcific aortic valve disease: A meta-analysis","authors":"Muhammad Omar Larik","doi":"10.1016/j.athplu.2023.09.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and aims</h3><p>Calcific aortic valve disease (CAVD) is a common valvular disease, prevalent particularly within the older age groups. The potential use of biomarkers in diagnosing and assessing the severity of CAVD, in supplementation with imaging techniques, has recently gained momentum within the field of cardiovascular medicine. Therefore, a meta-analysis was performed that assessed the association between the fetuin-A levels, and the presence of CAVD.</p></div><div><h3>Methods</h3><p>PubMed and Cochrane were searched from inception to April 2023. Risk of bias was assessed using the Newcastle-Ottawa scale for cohort studies.</p></div><div><h3>Results</h3><p>This analysis includes a total of 3,280 patients with CAVD, and 7,505 patients as control, resulting in the pooling of 10,785 patients in this meta-analysis. It was observed that the circulating levels of fetuin-A were significantly lowered in patients with CAVD (SMD: -0.20; 95% CI: -0.39, -0.02; P = 0.03). Moreover, the analysis revealed that fetuin-A levels had no significant association with CAVD in patients suffering from kidney disease (SMD: 0.20; 95% CI: -0.46, 0.85; P = 0.56).</p></div><div><h3>Conclusion</h3><p>While initial results demonstrate the potential effectiveness, further research is essential in order to arrive at a robust conclusion regarding the use of fetuin-A as a diagnostic biomarker for calcific aortic valve disease.</p></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"54 ","pages":"Pages 27-29"},"PeriodicalIF":1.4000,"publicationDate":"2023-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562872/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Atherosclerosis plus","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S266708952300041X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

Abstract

Background and aims

Calcific aortic valve disease (CAVD) is a common valvular disease, prevalent particularly within the older age groups. The potential use of biomarkers in diagnosing and assessing the severity of CAVD, in supplementation with imaging techniques, has recently gained momentum within the field of cardiovascular medicine. Therefore, a meta-analysis was performed that assessed the association between the fetuin-A levels, and the presence of CAVD.

Methods

PubMed and Cochrane were searched from inception to April 2023. Risk of bias was assessed using the Newcastle-Ottawa scale for cohort studies.

Results

This analysis includes a total of 3,280 patients with CAVD, and 7,505 patients as control, resulting in the pooling of 10,785 patients in this meta-analysis. It was observed that the circulating levels of fetuin-A were significantly lowered in patients with CAVD (SMD: -0.20; 95% CI: -0.39, -0.02; P = 0.03). Moreover, the analysis revealed that fetuin-A levels had no significant association with CAVD in patients suffering from kidney disease (SMD: 0.20; 95% CI: -0.46, 0.85; P = 0.56).

Conclusion

While initial results demonstrate the potential effectiveness, further research is essential in order to arrive at a robust conclusion regarding the use of fetuin-A as a diagnostic biomarker for calcific aortic valve disease.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
胎儿素A水平与钙化主动脉瓣疾病相关:一项荟萃分析
背景和目的钙化性主动脉瓣病(CAVD)是一种常见的瓣膜病,尤其在老年人群中流行。生物标志物在诊断和评估CAVD严重程度方面的潜在用途,加上成像技术,最近在心血管医学领域获得了发展势头。因此,进行了一项荟萃分析,评估胎球蛋白-a水平与CAVD存在之间的关系。方法从开始到2023年4月检索PubMed和Cochrane。使用纽卡斯尔-渥太华量表进行队列研究,评估偏倚风险。结果该分析共包括3280名CAVD患者,7505名患者作为对照,结果在该荟萃分析中汇集了10785名患者。CAVD患者血清胎球蛋白-A水平显著降低(SMD:-0.20;95%CI:-0.39,-0.02;P=0.03),分析显示,在肾病患者中,胎球蛋白-A水平与CAVD没有显著相关性(SMD:0.20;95%CI:0.460.85;P=0.56),为了得出关于使用胎蛋白-a作为钙化性主动脉瓣疾病的诊断生物标志物的有力结论,进一步的研究是至关重要的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Atherosclerosis plus
Atherosclerosis plus Cardiology and Cardiovascular Medicine
CiteScore
2.60
自引率
0.00%
发文量
0
审稿时长
66 days
期刊最新文献
Adherence to the Healthy Nordic Food Index is associated with reduced plasma levels of inflammatory markers in patients with heterozygous familial hypercholesterolemia A collaborative effort across Africa to investigate risk factors and outcomes of premature acute coronary syndrome: Protocol for the EAS Lipid Registry of Africa (LIPRA) Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials Lipoprotein(a) and the atherosclerotic burden – Should we wait for clinical trial evidence before taking action? Coronary artery calcification score and 19 biomarkers on cardiovascular events; a 10-year follow-up DanRisk substudy
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1